Age-related macular degeneration (AMD)

AMD, or age-related macular degeneration, is a leading cause of vision loss for Americans age 50 and older. It affects central vision, where sharpest vision occurs, causing difficulty conducting daily tasks such as driving, reading, and recognizing faces.

The therapeutic market for wet AMD is over $10 billion. More than half of wet AMD patients on anti-VEGF treatments continue to experience vision loss over time due to the development of subretinal fibrosis. There are currently no effective therapies to prevent or treat fibrosis.

AivoCode is developing a first-in-class intravitreal therapeutic to inhibit subretinal fibrosis, a known and unaddressed complication in patients with wet AMD. This program is based on the use of camelid single domain nanobodies (VHH) that block the activity of a known inflammatory and fibrotic factor that contributes to the development of subretinal fibrosis.

This program is being supported by a NIH SBIR grant.